Format for disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A - Details of the Acquisition


Name of the Target Company (TC)	**SOTAC PHARMACEUTICALS LIMITED**		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	**CRAFT EMERGING MARKET FUND PCC - CITADEL CAPITAL FUND** **CRAFT EMERGING MARKET FUND PCC - ELITE CAPITAL FUND**		
Whether the acquirer belongs to Promoter / Promoter group	**NO**		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	**NSE**		
Details of the acquisition as follows	Number	% w.r.t.total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of: a) Shares carrying voting rights b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others) c) Voting rights (VR) otherwise than by shares d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) e) Total (a+b+c+d)	**NIL**	**NIL**	**NIL**
Details of acquisition a) Shares carrying voting rights acquired b) VRs acquired otherwise than by equity shares c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	**861,600**	**7.79**	**7.79**

d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others) e) Total (a+b+c+/-d)			
After the acquisition, holding of acquirer along with PACs of: a) Shares carrying voting rights b) VRs otherwise than by equity shares c) Warrants/convertible securities /any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others) e) Total (a+b+c+d)	**861,600**	**7.79**	7.79
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer / encumbrance, etc.)	**OPEN MARKET**		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	**NOT APPLICABLE**		
Date of acquisition of / date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	**20 FEB 2025 / 03 MAR 2025 / 05 MAR 2025 / 11 MAR 2025 12 MAR 2025 / 13 MAR 2025/ 18 MAR 2025 / 20 MAR 2025 21 MAR 2025 / 18 JUN 2025 / 19 JUN 2025 / 27 JUN 2025 30 JUN 2025 / 01 JULY 2025 / 10 MAR 2026 / 13 MAR 2026**		
Equity share capital / total voting capital of the TC before the said acquisition	**861,600 / 11,050,000**		
Equity share capital/ total voting capital of the TC after the said acquisition	**861,600 / 11,050,000**		
Total diluted share/voting capital of the TC after the said acquisition	**861,600 / 11,050,000**		

Part-B***

Name of the Target Company:

Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquirer and/ or PACs
CRAFT EMERGING MARKET FUND PCC - CITADEL CAPITAL FUND	**NO**	
CRAFT EMERGING MARKET FUND PCC - ELITE CAPITAL FUND	**NO**	



Signature of the acquirer / Authorised Signatory

Place: **MAURITIUS**

Date: **30 MARCH 2026**

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.